FDA-AE-T13

Subjects With Common Adverse Events Occurring at ≥X% Frequency

Safety Population

Preferred Term [1]	Xanomeline Low Dose (N=XX) n (%)	Xanomeline High Dose (N=XX) n (%)	Placebo (N=XX) n (%)	Risk Difference (%) (95% CI) [2]	Risk Difference (%) (95% CI) [3]
PT	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)

Source: ADAE; Program name: fda-ae-t13.sas;

Abbreviations: CI, confidence interval; MedDRA, Medical Dictionary for Regulatory Activities; N, number of subjects in treatment arm; n, number of subjects with adverse event; PT, preferred term

Note: Subjects are counted once within each preferred term.

[1] Treatment-emergent adverse event is defined as AE with onset after the first dose of study drug. Table display is ordered by the highest frequency in Xanomeline High Dose group. All adverse events were coded using MedDRA version xx.x.

[2] Difference is shown between Xanomeline Low Dose vs. Placebo.

[3] Difference is shown between Xanomeline High Dose vs. Placebo.

Programming Notes: Program this table for common AE occurring at ≥5% frequency.